Relapsed/Refractory Multiple Myeloma (RRMM)Phase 1NCT07874334
Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis
A Phase 1 study testing GPRC5D CART in people with Relapsed/Refractory Multiple Myeloma (RRMM) and Light-Chain Amyloidosis, run by Hadassah Medical Organization at 1 site in Israel.
Trial summary
A Phase 1a/b Open-Label Study to Evaluate Safety and Preliminary Efficacy of GPRC5D CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Relapsed/Refractory Multiple Myeloma (RRMM), Light-Chain Amyloidosis
- What is being tested?
- GPRC5D CART
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 160 participants
- Where
- 1 siteIsrael
- Study dates
- 1 Nov 2026to 31 Dec 2032
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ≥18 years of age at the time of signing informed consent.
- Voluntarily signed informed consent form.
- Diagnosis of relapsed/refractory multiple myeloma or AL amyloidosis, with measurable disease at screening visit as follows:
- Multiple Myeloma (at least one of the criteria below):
- Serum M-protein greater or equal to 0.5 g/dL.
- Positive test for urine M-protein.
Show all 25Show fewer
- Serum free light chain (FLC) assay: involved FLC level greater or equal to 3 mg/dL (30 mg/L) provided serum FLC ratio is abnormal.
- A biopsy- or PET-CT- proven evaluable plasmacytoma*.
- Bone marrow plasma cells > 10% of total bone marrow cells*.
- Non secretory patient will be allowed provided they have measurable disease by PET-CT or MRI or bone marrow aspiration, as designated*.
- Results pre-dating the Screening visit by up to 28 days may be used to establish eligibility AL Amyloidosis Serum free light chain (FLC) assay: involved FLC level greater or equal to 3 mg/dL (30 mg/L) provided serum FLC ratio is abnormal.
- Prior Exposure:
- Multiple Myeloma: Subject must have been exposed to at least 3 prior lines of therapy including the following agents:
- proteasome inhibitor
- immunomodulatory (IMiDs) drug
- anti-CD38 antibody
- AL Amyloidosis: Subject have been exposed to 2 prior lines of therapy which include/s the following agents:
- proteasome inhibitor
- anti-CD38 antibody
- Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.
- Women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or tubal ligation or who has not been naturally postmenopausal for at least 24 consecutive months, must have a negative serum pregnancy test prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use effective methods of birth control throughout the study.
- Recovery to ≤ Grade 2 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 3 neuropathy.
- Ability and willingness to adhere to the study visit schedule and all protocol requirements.
- Subjects who have previously undergone allogenic stem cell transplantation are without evidence of graft versus host disease after cessation of any immunosuppressive therapy for at least one month before recruitment to the study.
- Subjects with Absolute Lymphocyte Count (ALC) > 0.3 × 109/L
Who cannot join
- Known bulky central nervous system disease.
- Inadequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN) and direct bilirubin > 4x ULN.
- Inadequate renal function defined by serum creatinine clearance/estimated clearance of <20 (ml/min).
- International ratio (INR) or partial thromboplastin time (PTT) > 2 x ULN, unless on a stable dose of anticoagulant for a thromboembolic event (provided this event is not an exclusion criteria).
- Inadequate bone marrow function defined by absolute neutrophil count (ANC) < 1000 cells/mm3, platelet count < 30,000 mm3, or hemoglobin < 8 g/dL.
- Echocardiogram with left ventricular ejection fraction < 40%.
Show all 21Show fewer
- Ongoing treatment with chronic immunosuppressant or systemic steroids (physiological replacement doses of steroids are allowed up to 12 mg/m2/d hydrocortisone or equivalent)
- Significant co-morbid condition or disease which in the judgment of the Investigator would place the subject at undue risk or interfere with the study; examples include, but are not limited to, cirrhotic liver disease, sepsis, recent significant traumatic injury, and other conditions.
- Known human immunodeficiency virus (HIV) positive status.
- Active Hepatitis B or Hepatitis C infections.
- Active CMV infection.
- Have suffered from a stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control and is not expected to resolve or stabilize within 3 months.
- Chronic atrial fibrillation with uncontrolled heart rate.
- Second primary malignancy that has required therapy in the last 2 years or is not in complete remission. This exclusion criterion does not exclude the following subjects: successfully treated non- metastatic basal cell or squamous cell skin carcinoma, or prostate cancer under control with hormonal therapy
- Subjects who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation and who meet any of the following criteria:
- Have been on a stable dose of anticoagulation for < 1 month (except for acute line insertion induced thrombosis).
- Have had a Grade 2, 3, or 4 hemorrhage in the last 30 days
- Are experiencing continued symptoms from their venous thromboembolic event (e.g. continued dyspnea or oxygen requirement).
- Pregnant or lactating women.
- Contraindication to a study treatment/procedure or is anticipated to receive treatment/procedure that may preclude performance of study procedures.
- Subjects with Absolute Lymphocyte Count (ALC) ≤0.3 × 109/L or < 300 cells/mm3 (due to potential challenges with producing CART cells), per investigator judgement
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Israel1 site
Hadassah MO
Jerusalem, 9574869
Polina Stepensky, MD, 97226776679, Fainak@haddasah.org.il
About this study
Official title: A Phase 1a/b Open-Label Study to Evaluate Safety and Preliminary Efficacy of GPRC5D CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis.
A Phase 1a/b Open-Label Study to Evaluate Safety and Preliminary Efficacy of GPRC5D CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis.
- Being tested
- GPRC5D CART
- Keywords
- Multiple Myeloma, Amyloidosis
- Medical subject headings
- Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis, Amyloidosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GPRC5D CARTBiological
The GPRC5D CART is defines as autologous bone marrow derived T-cells transduced with anti-GPRC5D CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human GPRC5D. The GPRC5D CART is provided cryopreserved.
| Study group | Role | What they receive |
|---|---|---|
| GPRC5D CART | Experimental | In the Phase 1a dose-escalation phase, eligible participants for Cohorts 1, 2, 3 and 4 will receive a single dose of either 50× 10˄6, 150 × 10˄6, 300 × 10˄6 or 450 × 10˄6 GPRC5D CART cells, respectively. The Phase 1b expansion part will enroll additional participants at the maximum tolerated dose, as determined during dose escalation. Receives: Biological: GPRC5D CART |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Treatment-Related Serious Adverse Events and Adverse Events of Special Interest following GPRC5D CART Therapy
Incidence of Treatment-Related Serious Adverse Events and Adverse Events of Special Interest will be assessed
Measured: 24 months following infusion
Maximum tolerated dose (MTD) of GPRC5D CART cells in Phase 1a.
The maximum tolerated single dose (MTD) of GPRC5D CART cells will be determined during Phase 1a dose-escalation stage.
Measured: 21 days following infusion
Secondary outcomes (5)
Overall response rate
Overall Response Rate is defined by proportion of subjects with Partial Response or better per IMWG Criteria for MM, and Partial Response or better per Hematologic Response Criteria for AL
Measured: 24 months following infusion
Complete response rate
Complete Response Rate is defined by proportion of subjects with Complete Response per IMWG Criteria for MM or per Hematologic Response Criteria for AL
Measured: 24 months following infusion
Progression-Free Survival
Progression-Free Survival is defined as the time from the date of the initial infusion the date of first documented disease progression, or death due to any cause, whichever occurs first
Measured: 24 months following infusion
Overall Survival
Overall Survival is defined by the date of the initial infusion to the date of the patient's death due to any cause
Measured: 24 months following infusion
MRD negativity rate
MRD Negativity Rate is defined by proportion of subjects with MRD, defined as the absence of clonal plasma cells on bone marrow aspirate (minimum test sensitivity to detect 1 in 10x5 nucleated cells (10-5 threshold))
Measured: At 1, 6, 12, 18, and 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Oct 2026
- Study start1 Nov 2026 (estimated)
- Primary completion31 Dec 2032 (estimated)
- Study completion31 Dec 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Relapsed/Refractory Multiple Myeloma (RRMM)Studies of the same condition, open and under way.
- More trials run by Hadassah Medical OrganizationThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- The phase 1a dose-escalation part will follow a 3+3 design and include up to 4 dose level cohorts. This will be followed by a phase 1b expansion part, in which participants will be enrolled to receive treatment at the maximum tolerated dose (MTD).
- Masking
- None (open label)
- Enrolment
- 160 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hadassah Medical Organization
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Polina Stepensky, Hadassah Medical Organization
- Investigators
- Polina Stepensky, MD, Principal investigator, Hadassah Medical Organization
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07874334
- Sponsor's protocol ID
- GPRC5D CART-01
- Status last verified
- Oct 2026
- First submitted
- 8 Oct 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1a/b Open-Label Study to Evaluate Safety and Preliminary Efficacy of GPRC5D CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis.
- ClinicalTrials.gov ID
- NCT07874334
- Acronym / sponsor ID
- GPRC5D CART-01
- Keywords
- Multiple Myeloma, Amyloidosis
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 160 participants (estimated)
- Lead sponsor
- Hadassah Medical OrganizationUniversity, hospital or other
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 31 Dec 2032 (estimated)
- Study completion
- 31 Dec 2032 (estimated)
- First posted
- 14 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Phase 1a/b Open-Label Study to Evaluate Safety and Preliminary Efficacy of GPRC5D CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- The phase 1a dose-escalation part will follow a 3+3 design and include up to 4 dose level cohorts. This will be followed by a phase 1b expansion part, in which participants will be enrolled to receive treatment at the maximum tolerated dose (MTD).
| Arm | Type | Receives |
|---|---|---|
| GPRC5D CART | Experimental | Biological: GPRC5D CARTIn the Phase 1a dose-escalation phase, eligible participants for Cohorts 1, 2, 3 and 4 will receive a single dose of either 50× 10˄6, 150 × 10˄6, 300 × 10˄6 or 450 × 10˄6 GPRC5D CART cells, respectively. The Phase 1b expansion part will enroll additional participants at the maximum tolerated dose, as determined during dose escalation. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (25 listed)
- ≥18 years of age at the time of signing informed consent.
- Voluntarily signed informed consent form.
- Diagnosis of relapsed/refractory multiple myeloma or AL amyloidosis, with measurable disease at screening visit as follows:
- Prior Exposure:
- Multiple Myeloma: Subject must have been exposed to at least 3 prior lines of therapy including the following agents:
Key exclusion criteria (21 listed)
- Known bulky central nervous system disease.
- Inadequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN) and direct bilirubin > 4x ULN.
- Inadequate renal function defined by serum creatinine clearance/estimated clearance of <20 (ml/min).
- International ratio (INR) or partial thromboplastin time (PTT) > 2 x ULN, unless on a stable dose of anticoagulant for a thromboembolic event (provided this event is not an exclusion criteria).
- Inadequate bone marrow function defined by absolute neutrophil count (ANC) < 1000 cells/mm3, platelet count < 30,000 mm3, or hemoglobin < 8 g/dL.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GPRC5D CARTThe GPRC5D CART is defines as autologous bone marrow derived T-cells transduced with anti-GPRC5D CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human GPRC5D. The GPRC5D CART is provided cryopreserved. | Biological | GPRC5D CART |
Primary outcome
Incidence of Treatment-Related Serious Adverse Events and Adverse Events of Special Interest following GPRC5D CART Therapy
Time frame: 24 months following infusion
Incidence of Treatment-Related Serious Adverse Events and Adverse Events of Special Interest will be assessed
Maximum tolerated dose (MTD) of GPRC5D CART cells in Phase 1a.
Time frame: 21 days following infusion
The maximum tolerated single dose (MTD) of GPRC5D CART cells will be determined during Phase 1a dose-escalation stage.
5 secondary outcomes
Overall response rate
Time frame: 24 months following infusion
Complete response rate
Time frame: 24 months following infusion
Progression-Free Survival
Time frame: 24 months following infusion
Overall Survival
Time frame: 24 months following infusion
MRD negativity rate
Time frame: At 1, 6, 12, 18, and 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Relapsed/Refractory Multiple Myeloma (RRMM)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
RecruitingPhase 1/2
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
RecruitingPhase 1
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Multiple Myeloma
RecruitingPhase 3
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Polina Stepensky, MD principal investigator
Hadassah Medical Organization
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing GPRC5D CART in people with Relapsed/Refractory Multiple Myeloma (RRMM) and Light-Chain Amyloidosis, run by Hadassah Medical Organization at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 25 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Polina Stepensky, MD (972-2-6778353, Fainak@hadassah.org.il), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Treatment-Related Serious Adverse Events and Adverse Events of Special Interest following GPRC5D CART Therapy (time frame: 24 months following infusion). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.